EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Severe agranulocytosis in patient with Graves’ disease on second exposure to carbimazole

Hady M Gad, Ammar W Ashor iD, Waqar Ahmad iD, Ahmed Hanafy, Barkavi Dhakshinamoorthy, Wael Elsaify, Simon Ashwell

Endocrinology, Diabetes & Metabolism Case Reports · 01.01.2026 · 2026 (1)

DOI: 10.1530/edm-25-0131 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Endocrinology, Diabetes & Metabolism Case Reports, online erschienen am 26.03.2026. Verfasst von Hady M Gad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes, James Cook Hospital, South Tees Hospitals NHS Foundation Trust, North Yorkshire, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For half a century, antithyroid drugs (ATDs) have been the first-line treatment for Graves’ disease. ATDs, e.g. carbimazole, are associated with minor and serious adverse effects. These include rash, urticaria, arthralgia, hepatotoxicity, vasculitis, and agranulocytosis. Agranulocytosis is a potentially serious adverse effect characterised by a neutrophil count <0.5 × 109 cells/L, which may deteriorate further into sepsis and death. This is a case report of a 47-year-old female who had a 17-year history of Graves’ disease. She received carbimazole for 2 years, which was stopped after remission. She presented with relapsed thyrotoxicosis in 2025 when carbimazole (40 mg) was reinstituted. Three weeks later, the patient self-presented to the hospital with sore throat, painful swallowing, and sweating. Examination found oral ulceration, pharyngeal erythema, and tender cervical lymphadenopathy. She was admitted to the hospital and treated under the endocrinology team as agranulocytosis, carbimazole was stopped, and she was treated per local guidelines of neutropenic sepsis. After agranulocytosis was resolved, the patient underwent total thyroidectomy. Despite being well-tolerated, doctors and patients should be well aware of this potentially serious adverse effect of carbimazole. Learning points

Schlagwörter

Stichwörter der Autor:innen

Graves’ diseaseadverse effectsagranulocytosisantithyroid drugscarbimazole

Autor:innen und Institutionen

  • Department of Endocrinology and Diabetes, James Cook Hospital, South Tees Hospitals NHS Foundation Trust, North Yorkshire, UK.
  • Department of Internal Medicine, College of Medicine, Al-Mustansiriayh University, Baghdad, Iraq.
  • Department of Endocrine Surgery, James Cook Hospital, South Tees Hospitals NHS Foundation Trust, North Yorkshire, UK.

ORCID-Profile: Ammar W Ashor, Waqar Ahmad

Zitieren

APA

Gad, H. M., Ashor, A. W., Ahmad, W., Hanafy, A., Dhakshinamoorthy, B., Elsaify, W., & Ashwell, S. (2026). Severe agranulocytosis in patient with Graves’ disease on second exposure to carbimazole. Endocrinology, Diabetes & Metabolism Case Reports, 2026(1). https://doi.org/10.1530/edm-25-0131

Vancouver

Gad HM, Ashor AW, Ahmad W, Hanafy A, Dhakshinamoorthy B, Elsaify W, et al. Severe agranulocytosis in patient with Graves’ disease on second exposure to carbimazole. Endocrinology, Diabetes & Metabolism Case Reports. 2026;2026(1). doi:10.1530/edm-25-0131

BibTeX
@article{Gad2026,
  author = {Gad, Hady M and Ashor, Ammar W and Ahmad, Waqar and Hanafy, Ahmed and Dhakshinamoorthy, Barkavi and Elsaify, Wael and Ashwell, Simon},
  title = {Severe agranulocytosis in patient with Graves’ disease on second exposure to carbimazole},
  journal = {Endocrinology, Diabetes & Metabolism Case Reports},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1530/edm-25-0131}
}
Kostenlos starten →